Table 2.
The impact of pretreatment TRL on the diagnostic performance of 18F-FDG-PET/CT during LN staging in gynecological cancer patients (primary cohort).
| Cervical cancer (n = 127) | Endometrial cancer (n = 203) | Ovarian caner (n = 96) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| False-positive PET/CT results | False-positive PET/CT results | False-positive PET/CT results | ||||||||
| Yes (n = 10) | No (n = 117) | P-value | Yes (n = 12) | No (n = 191) | P-value | Yes (n = 8) | No (n = 88) | P-value | ||
| WBC count (/μL) | <9000 | 4 (3.6) | 106 (96.4) | <0.0001 | 5 (2.7) | 181 (97.3) | <0.0001 | 3 (3.6) | 81 (96.4) | <0.0001 |
| ≥9000 | 6 (35.3) | 11 (64.7) | 7 (41.2) | 10 (58.8) | 5 (41.7) | 7 (58.3) | ||||
Statistical significance was assessed using two-sided Fisher’s exact test.
FDG fluorodeoxyglucose, PET positron emission tomography, CT computed tomography, WBC white blood cell.